Literature DB >> 8516591

Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

M S Pepe1, M Mori.   

Abstract

In the context of competing risks the Kaplan-Meier estimator is often unsuitable for summarizing failure time data. We discuss some alternative descriptive methods including marginal probability and conditional probability estimators. Two-sample test statistics are also presented.

Mesh：

Year:  1993        PMID： 8516591     DOI： 10.1002/sim.4780120803

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  133 in total

Review 1.  Logistic or Cox model to identify risk factors of nosocomial infection: still a controversial issue.

Authors:  S Chevret
Journal:  Intensive Care Med       Date:  2001-10       Impact factor: 17.440

2.  Sex differences in new-onset heart failure.

Authors:  Sven Meyer; Frank P Brouwers; Adriaan A Voors; Hans L Hillege; Rudolf A de Boer; Ron T Gansevoort; Pim van der Harst; Michiel Rienstra; Isabelle C van Gelder; Dirk J van Veldhuisen; Wiek H van Gilst; Peter van der Meer
Journal:  Clin Res Cardiol       Date:  2014-11-15       Impact factor: 5.460

3.  Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study.

Authors:  Jop C Teepen; Judith L Kok; Leontien C Kremer; Wim J E Tissing; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Dorine Bresters; Helena J van der Pal; Birgitta Versluys; Eline van Dulmen-den Broeder; Tamar Nijsten; Michael Hauptmann; Nynke Hollema; Wil V Dolsma; Flora E van Leeuwen; Cécile M Ronckers
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

4.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

5.  Lung Cancer Prognosis in Elderly Solid Organ Transplant Recipients.

Authors:  Keith Sigel; Rajwanth Veluswamy; Katherine Krauskopf; Anita Mehrotra; Grace Mhango; Carlie Sigel; Juan Wisnivesky
Journal:  Transplantation       Date:  2015-10       Impact factor: 4.939

6.  Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.

Authors:  Anne M Butler; Andrew F Olshan; Abhijit V Kshirsagar; Jessie K Edwards; Matthew E Nielsen; Stephanie B Wheeler; M Alan Brookhart
Journal:  Am J Kidney Dis       Date:  2015-02-07       Impact factor: 8.860

7.  Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.

Authors:  J de la Rubia; G Martín; J Martínez; I Lorenzo; G Sanz; I Jarque; F Moscardó; C Jiménez; P Lorente; A Camps; M A Sanz
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

8.  Prediagnostic use of hormone therapy and mortality after breast cancer.

Authors:  Polly A Newcomb; Kathleen M Egan; Amy Trentham-Dietz; Linda Titus-Ernstoff; John A Baron; John M Hampton; Meir J Stampfer; Walter C Willett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

Review 9.  Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Authors:  Jeremy Franklin; Dennis A Eichenauer; Ingrid Becker; Ina Monsef; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2017-09-13

10.  Laparoscopic versus open colectomy for TNM stage III colon cancer: results of a prospective multicenter study in Italy.

Authors:  Mario Guerrieri; Roberto Campagnacci; Angelo De Sanctis; Giovanni Lezoche; Paolo Massucco; Massimo Summa; Rosaria Gesuita; Lorenzo Capussotti; Giuseppe Spinoglio; Emanuele Lezoche
Journal:  Surg Today       Date:  2012-08-19       Impact factor: 2.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.